US WorldMeds Completes Phase III Trial Of Lofexidine For Treatment Of Opiate Withdrawal Symptoms
US WorldMeds, a Kentucky-based specialty pharmaceutical company, announced that a recently completed Phase III clinical trial investigating the use of lofexidine hydrochloride (Lofexidine) for the treatment of opiate withdrawal symptoms in patients undergoing opiate detoxification has shown that
More: continued here